New chagas drug candidate passes first safety test in small trial

NCT ID NCT05523596

Completed Disease control Sponsor: IC-MedTech Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested the safety of an experimental drug called ICM20 in 13 adults with Chagas disease who had not been treated before. Participants took ICM20 along with the standard drug benznidazole. The main goal was to check for side effects and see how many people stayed on the medication for 60 days. Since this was a small safety study, it does not yet show whether ICM20 works better than existing treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ICM20 (a small molecule drug) and benznidazole (a standard Chagas drug)
What this could lead to: If safe, this could support further studies of ICM20 for treating Chagas disease.
What could go wrong: This is a very early Phase 1 safety trial with only 13 participants, so it cannot prove effectiveness. Side effects or lack of benefit may emerge in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHAGAS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chagas disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SAFETY ISSUES

Contacts and locations

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
Culmore Clinic

Falls Church, Virginia, 22044, United States
Parkway Medical

Glen Burnie, Maryland, 21061, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.